Ovarian Cancer

Results from NRG-GY019 establish chemotherapy followed by letrozole as the definitive SOC for newly diagnosed stage II-IV low-grade serous ovarian carcinoma

Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

CTIM-76 received fast track designation from the FDA for pretreated platinum-resistant ovarian cancer.

Pembrolizumab plus paclitaxel, with or without bevacizumab, is approved in the EU for pretreated platinum-resistant ovarian cancer with PD-L1 expression.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

The FDA cleared relacorilant plus nab-paclitaxel in ovarian cancer, the primary end point of the SENTRY trial in myelofibrosis was met, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The PI3Kα inhibitor risovalisib has been approved in Japan for PIK3CA-mutated ovarian clear cell carcinoma after progression on chemotherapy.

The FDA approved relacorilant plus nab-paclitaxel for previously treated platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer.

The top 5 OncLive TV videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, lung cancer, breast cancer, and prostate cancer.

The FDA has cleared nivolumab/AVD for classical Hodgkin lymphoma, accepted a bezuclastinib NDA for review in nonadvanced systemic mastocytosis, and more.

Emese Zsiros, MD, PhD, FACOG, discusses the FDA approval of pembrolizumab plus paclitaxel with or without pembrolizumab for PD-L1–positive ovarian cancer.

The regulatory agency green lit the use of MyChoice CDx as a companion diagnostic for niraparib in advanced ovarian cancer

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

Data from KEYNOTE-B96 supported the first FDA approval of an immunotherapy regimen in PD-L1–positive platinum-resistant, recurrent ovarian cancer.

KEYNOTE-B96 showed that pembrolizumab plus paclitaxel improved PFS and OS vs chemotherapy alone in platinum-resistant ovarian cancer.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

The FDA approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic for patients with PD-L1–positive ovarian cancer who could receive pembrolizumab.

The FDA has approved pembrolizumab plus paclitaxel with/without bevacizumab for PD-L1–positive platinum-resistant ovarian cancer.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

Alexander B. Olawaiye, MD, discusses updated OS data from the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in PROC.

OncLive spoke to 4 experts in order to unpack the top data presented during oncology conferences over the course of 2025.

Drs Matulonis and Porter discuss the role of immunotherapy in gynecologic cancer management, focusing on clinical breakthroughs and future directions.

The predictive value of PD-L1 expression on response to chemoimmunotherapy was greater on metastatic lesions vs primary tumors in HGSOC.